2|0|Public
40|$|Eine paradoxe Embolie kommt als Schlaganfallätiologie in Frage, wenn ein kardialer Rechts-Links-Shunt diagnostiziert wurde und andere Ursachen ausgeschlossen wurden. Die Diagnosestellung erfolgte bisher durch transösophageale Echokardiographie (TEE) und war in der Frühphase nach Hirninfarkt nur einge-schränkt möglich. In der vorliegenden Arbeit wird daher ein einfaches, nicht-invasives Untersuchungsverfahren mit transkranieller Dopplersonographie und nicht-lungengängigem Ultraschallkontrastmittel zur Detektion eines Rechts-Links-Shunts vorgestellt (Mikrobläschentest mit Echovist®). Im Vergleich mit dem TEE wurde bei 50 Patienten eine Sensitivität von 0, 47 und eine Spezifität von 0, 99 unter Ruhebedingungen ermittelt. Eine Untersuchung während eines Valsalva Manövers zur intraatrialen Druckerhöhung im rechten Vorhof konnte die Sensitivität auf 0, 91 bei unveränderter Spezifität steigern. Zur Optimierung und Vereinheitlichung dieser Untersuchungstechnik wurde durch den Verfasser ein strukturiertes Verfahren zur Konsensbildung initiiert. Nach Sichtung der aktuellen Literatur wurde eine Diskussionsgrundlage erstellt und von den Teilnehmern bewertet. Eine Konsenskonferenz unter Federführung des Verfas-sers stimmte Details der Untersuchungstechnik ab und publizierte die Ergebnisse in einer internationalen Fachzeitschrift. Eine Untersuchung der Wertigkeit bildgebender Verfahren bei paradoxer Hirnembolie an 87 Patienten zeigte, dass die computertomographisch ermittelte Ausdehnung des Hirninfarktes nicht von der dopplersonographisch bestimmten funktionellen Relevanz eines Rechts-Links-Shunt oder dem Vorliegen eines Vorhofseptumaneurysmas abhängt. Bei der diffusionsgewichteten Magnetresonanztomographie (DWI-MRT) kann das Muster der Signalveränderungen Informationen über die Hirninfarktätiologie geben. Bei 32 Patienten bis zum 60. Lebensjahr mit unterschiedlicher Infarktätiologie, unter Ausschluss von Makroangiopathie oder kardialer Emboliequelle, konnte ge-zeigt werden, dass ein embolisches Läsionsmuster (mehr als eine akute Läsion) im DWI-MRT mit dem Vorliegen eines OFO assoziiert ist (positiver Vorhersagewert = 0, 81), während im Falle anderer Ätiologien lediglich mit einer Wahrschein-lichkeit von 0, 13 ein embolisches Muster zu erwarten ist. Für die Wahl der Sekundärprophylaxe ist die Kenntnis der Rezidivrate nach paradoxer Hirnembolie wichtig. Wir beobachteten daher 90 Patienten mit paradoxer Hirnembolie und medikamentöser Sekundärprophylaxe über einen Zeitraum bis zu 10 Jahren. Das jährliche Risiko für den kombinierten Endpunkt Hirninfarkt oder transitorisch-ischämische Attacke betrug 1, 6 % (kumulatives Risiko = 15 %) und für den Endpunkt Hirninfarkt 0, 4 % (kumulatives Risiko = 4, 2 %). Die Kaplan-Meier Schätzung konnte für Patienten mit konkurrierender Ätiologie (Diabetes mellitus, Hypertonie) eine signifikante Verkürzung des rezidivfreien Intervalls aufzeigen. Die vorliegenden Daten zeigen, dass die Rezidivrate nach paradoxer Hirn-embolie unter medikamentöser Therapie gering ist, aber nicht völlig vernachlässigt werden kann. Eine generelle Empfehlung, über medikamentöse Sekundärprophylaxe hinausgehend, einen transfemoralen oder operativen Verschluss bei offenem Fora-men ovale nach Hirninfarkt durchzuführen, kann nicht gegeben werden. Eine derar-tige Maßnahme sollte Patienten mit offenem Foramen ovale und Vorhofseptumaneurysma oder Rezidivinsult bei Fehlen von konkurrierenden Ursachen vorbehalten bleiben. A {{paradoxical}} embolism {{is considered}} {{as the cause}} for a stroke etiology when a cardiac right-to-left shunt is diagnosed and other causes of stroke are excluded. Diagnosis of right-to-left shunt usually requires transesophageal echocardiography and is difficult to perform in acute stroke patients. The current paper introduces a simple, non-invasive procedure using transcranial dopplersonography and non-lung-passing ultrasound contrast agent to detect a right-to-left shunt (microbubble test with Echovist®). Examining 50 patients with TEE and microbubble test simultaneously, we found a sensitivity of 0. 47 and a specificity of 0. 99 for baseline conditions (without valsalva). A repeated test during Valsalva maneuver to increase the right <b>intracardial</b> <b>pressure</b> we found a sensitivity of 0. 91 while specificity remained unchanged [...] To optimize the examination technique and to facilitate exchange of examination results within study centers, {{the author of this}} paper initiated a structured consensus. After review of current literature all considered papers were reviewed and ranked according to generally acknowledged criteria for evidence based medicine. A consensus conference discussed details of examination technique and published the results in a medical journal. Examining the contribution of neuroimaging procedures for workup of patients with presumed paradoxical embolism in 87 patients, we found, that the size of infarct lesion according to the computertomography is not associated with the functional impact of the right-to-left shunt or with the presence of an atrial septal aneurysm. Using diffusion weighted magnetic resonance tomography (DWI-MRT), we found in 32 patients younger or equal 60 years with different stroke etiology excluding large artery sclerosis or cardiac source of embolism, that an embolic lesion pattern in DWI-MRT is highly associated with the presence of a patent foramen ovale (positive prediction value = 0. 81). In case of a different etiology (no paradoxical embolism) there was only a 0. 13 probability for an embolic pattern in DWI-MRT. Knowledge of recurrence rate is crucial for choice of treatment for secondary prevention. We observed 90 patients with paradoxical embolism and medical treatment for up to 10 years to evaluate the recurrence rate. Actuarial risk for recurrence for the combined endpoint stroke or transient ischemic attack was 1. 6 % (cumulative risk = 15 %). Actuarial risk for the endpoint stroke was 0. 4 % (cumulative risk = 4. 2 %). Kaplan-Meier estimation revealed a significant difference for the recurrence-free interval, that was lower in patients with concurrent etiology such as hypertension and diabetes. These data demonstrate, that recurrence rate after paradoxical brain embolism is lower than in previous reports but cannot be completely neglected. A general recommendation for secondary prophylactic measures beyond medical treatment such as transfemoral closure of patent foramen ovale after stroke and assumed paradoxical embolism cannot be derived on the base of these data. These measures should be limited to patients with patent foramen ovale and atrial septal aneurysm or recurrent stroke when concurrent risk factors such as hypertension are lacking...|$|E
40|$|Introduction and {{background}} Viral myocarditis {{is a major}} health problem: up to 40 % of sudden death in young people is due to myocarditis – adverse inflammation – in the heart (1). A lot of viruses can cause myocarditis, but especially rhinoviruses and enteroviruses are responsible pathogens (2). Cardiac inflammation plays {{a central role in}} myocarditis and heart failure, mediating cardiac hypertrophy, myocyte death and fibrosis. Identification of targets that explain why one person does get adverse cardiac inflammation, whereas many others are spared, is crucial to better understand this disease and to develop new therapeutic tools (3). The discovery of micro-RNAs (miRs), a new class of small non-coding RNAs, is among the major scientific breakthroughs in recent years. They are crucial players in the regulation of gene expression by binding to messenger RNAs (mRNAs) and inhibiting their translation into protein (4). Global goals of this project MiRs have been implicated in the pathophysiology of cancer, infectious disorders, and hypertensive and ischemic heart disease (5). However, their involvement in cardiac inflammation during viral myocarditis is largely unknown. The overall objective of this project is to unravel the precise biological roleof specific inflammation-mediated miR- 221 and - 222 in cardiac injury and dysfunction following viral infection, and in cardiac hypertrophy and fibrosis development. Whereas recent studies (6) mainly focused on the role of cardiomyocyte- and fibroblast-derived miRs in hypertrophy, fibrosis and arrhythmias, this project will unravel the biological role – and determine their upstream regulation – of inflammation-mediated miR- 221 and - 222 in cardiac inflammatory disease. Preliminary data In a mouse model of human Coxsackievirus B 3 (CVB 3) induced myocarditis, the comparison of miR profiles at baseline using a miR microarray resulted in the identification and further validation via quantitativertPCR of miR- 221 and - 222 as inflammation-related miRs, beside miR- 146,- 155 and - 223 (7). We validated miRNA- 221 and - 222 as relevant targets mediating cardiac inflammation in viral myocarditis. However, their pathophysiologic role in cardiac inflammation is largely unknown. Recently, we obtained clear evidence that the absence of miR- 155 (part of another project) in mice resulted in a higher mortality, with increased cardiac inflammation and injury in CVB 3 -myocarditis. Whereas lack of miR- 155 in mice did not affect cardiac development or function at baseline, it resulted in increased cardiac inflammation and mortality compared to wild type littermates in CVB 3 -myocarditis (8). Fifty two percent (12 / 23) of miR- 155 knockout mice died within 8 days after CVB 3 -infection compared to 6 percent of wild types (1 / 15), with increased cardiacinflammation and injury but a similar CVB 3 -load in miR- 155 knockout mice. Hypothesis and specific aims of this project Both miR- 221 and - 222 are implicated in cancer formation and T-cell function, and have been found to modulate myogenesis (9). They are both up regulated by ERK 1 / 2, a cell signaling pathway which is crucial in cardiac hypertrophy and fibrosis. Further encouraged by the preliminary data described above, and well-knowing that raised levels of the inflammation-related miR- 221 and - 222 are present in both viral myocarditis and hypertensive HD, we postulate that: MiR- 221 and - 222 are key regulators of cardiac inflammation in viral myocarditis. Therefore we will unravel the precise biological function of miR- 221 and - 222 in knockout animals and by using antagomirs. We will also determine their mRNA-targets and pathways, and study their upstream regulation, explaining their possible implication in viral myocarditis. MiR- 221 and - 222 may be diagnostic tools and prognostic biomarkers for the severity of heart failure in viral heart disease. We aim to translate our findings to human viral myocarditis by studying miR levels in blood samples and inflammatory cardiac tissue biopsies. We will study whether miR- 221 or - 222 expression is raised in the blood of patients with myocarditis compared to controls, and whether quantification of miR- 221 or - 222 signifies a prognostic value in HF patients. Methodology 1 a. What is the biological role of miR- 221 and - 222 in heart failure? Do they protect against exaggerated inflammation and tissue damage? The severity of cardiac inflammation, fibrosis, tissue damage and dysfunction will be measured in miR- 221 or miR- 222 gene-inactivated mice (currently available) and compared to wild type mice. We will also use the commercially available antagomir-approach for these miRs, allowing an efficient and time-dependent way of miR-silencing (10). To obtain miR- 221 and - 222 overexpression or knockdown (with miR-spounges), an adeno-associated virus (AAV-mediated) method will be used (11). The following experimental conditions will be evaluated: (a) angiotensin-II induced hypertension, 7 and 28 days; (b) human Coxsackievirus B 3 -induced myocarditis, 7 and 35 days; (c) myocardial infarction by persistent left coronary ligation, 7 and 14 days. Heart function will be quantified with ultrasound- and electrocardiography, and by invasive <b>intracardial</b> <b>pressure</b> measurements. After obduction, hearts will be prepared for histological and molecular investigations. Haematoxylin-eosin staining, Siriusred (collagen) staining, immunohistochemistry of CD 45 -leucocytes, CD 3 -,CD 4 -, and CD 8 -lymfocytes, CD 68 -macrophages, CD 31 -capillars, and α-smooth muscle cell-actin coronary arteries. Expression of miR- 221 and - 222 in the heart will be evaluated with rtPCR and in situ hybridization. 1 b. What are the mRNA-targets of miR- 221 and - 222 in inflammatory cells, fibroblasts and cardiomyocytes? To address which pathways and targets are really functional, and may explain the phenotype observed in in vivo studies, we will combine in vivo and in vitro approaches of pathway analysis and specific target confirmation. We will combine transcriptome, miRNAome and proteome, in order to get gene network analyses and informatics-driven reconstruction of complex interactions. We will perform promoter analysis using Genomatix software (mRNAs and miRs), and we will link mRNA expression to microRNA expression profiles. We intend to investigate whether ERK- 1 and/or - 2 is a target pathway for miR- 221 and - 222 in cardiomyocytes versus fibroblasts. We will also investigate and confirm presumed targets by means of TargetScan and MiRanda. Predicted targets for miR- 221 and - 222 in myocarditis and hypertensive HD could be elements of the cytoskeleton {myosin, actin and sarcoglycan (hypertrophy) }, matrix metalloproteinase- 3 (MMP- 3) which activates MMP- 9 (inflammation and dilatation), smad- 2 and - 3, involved in transforming growth factor β (fibrosis). These targets will be validated in vitro in miR- 221 and - 222 (a) overexpressing(by means of lentiviral overexpression), (b) knockdown (using antagomirs), and (c) control cell populations (i. e. monocytes, fibroblasts and cardiomyocytes). Finally, luciferase reporter experiments, wherein 3 ’-UTR of target-mRNA is ligated to luciferase reporters, will give us theability to confirm these experiments. All necessary logistic and experimental infrastructure is available in the lab. 2. Are miR- 221 and - 222 useful diagnostic tools and biomarkers for inflammation and for heart failure? Different groups reported that miRNAs are circulating freely in human plasma and serum with marked biostability. Serum profiling performed in routine blood tests opens a window of opportunity for miR biomarker determinations, as RNA detection methods have much higher sensitivity and specificity than currently used protein detection assays (12). We will quantify miR expression in blood and cardiac muscle samples of patients with different kinds of heart failure, compared to a control population. In biopsies, we routinely isolate mRNA (for determination of RNA viruses such as CVB 3) {{in such a way that}} miRs can also be measured. We will use biopsies of patients with (a) acute ischemia; (b) hypertension; (c) viral myocarditis (in cooperation with prof. dr. A. Frustaci, Rome and prof. dr. H. Schultheiss, Berlin); and (d) control hearts. Already more than 250 blood and cardiac muscle biopsies have been sampled, obtained from patients of the clinicalheart failure unit (UZ Leuven) with ischemic (n= 65), hypertensive (n= 50) or viral heart disease (n= 150). Expected results We expect that our study of miR- 221 and - 222 in cardiac pathology will lead to a better understanding of their role in inflammatory cardiomyopathies and of viral myocarditis in particular, to a better physiopathological view of hypertrophy and fibrosis in heart failure, to a non-invasive biomarker of heart failure and of viral myocarditis, and eventually toa potential therapeutic target in these settings (13). Embedding of the project Research will be performed in contribution withprof. dr. Peter Carmeliet of the Vesalius Research Center, Flemish Institute for Biotechnology, KULeuven. Bench-to-bedside transformation will be achieved via cooperation with the clinical department of Cardiology UZ Leuven, under guidance of prof. dr. Frans Van de Werf. International collaboration with CARIM (Cardiovascular Research Institute Maastricht) is guaranteed thanks to prof. dr. Stephane Heymans (Maastricht and Leuven), who will help to coordinate this research project. References 1. Schultz JC etal. Diagnosis and treatment of viral myocarditis. Mayo Clin Proc 2009; 84 : 1001 - 9. 2. Dennert R, Crijns HJ and Heymans S. Acute viral myocarditis. Eur Heart J 2008 Jul 9 (epub ahead of print). 3. Heymans S. Inflammation and cardiac remodeling during viral myocarditis. Ernst Schering Res Found Workshop 2006; 55 : 197 - 218. 4. Gilad S et al. Serum microRNAs are promising novel biomarkers. PLoS One 2008 : 3; e 3148. 5. Grosshans H and Slack FJ. Micro-RNAs: small is plentiful. J Cell Biol 2002; 156 : 17 - 21. 6. Schroen B and Heymans S. MicroRNAs and beyond. The heart reveals its treasures. Hypertension 2009, 54 : 1189 - 94. 7. Latronico MV, Catalucci D, Condorelli G. Emerging role of microRNAs in cardiovascular biology. Circ Res 2007; 101 : 1225 - 36. 8. Worm J et al. Silencing of microRNA- 155 in mice during acute inflammatory response leads to derepression of c/ebp Beta and down-regulation of G-CSF. Nucleic Acids Res 2009; 37 : 5784 - 92. 9. Pedersen I, David M. MicroRNAs in theimmune response. Cytokine 2008; 43 : 391 - 94. 10. Krutzfeldt J et al. Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005; 438 : 685 - 9. 11. Pacak CA et al. Recombinant adeno-associated virus serotype 9 leads to preferential cardiac transduction in vivo. Circ Res 2006; 99 : e 3 - 9. 12. Jackson DB. Serum-based microRNAs: are we blinded by potential?Proc Natl Acad Sci 2009; 106 : E 5. 13. van Rooij E, Marshall WS and Olsen EN. Toward microRNA-based therapeutics for heart disease: the sense in antisense. Circ Res 2008; 103 : 919 - 28. status: publishe...|$|E

